A frequently cited meta-analysis found berberine produced roughly four pounds of average weight loss, while semaglutide trials average around 15% of body weight
GLP-1s offer significant promise to millions of Americans living with obesity, diabetes and/or cardiovascular disease, but their unprecedented demand and high price tags are creating challenging downstream impacts, including fluctuating supply, inconsistent clinical support, and runaway cost trajectory, said an Evernorth statement
These symptoms vary in intensity between patients, and physicians say to observe for symptoms such as intense pain or jaundice
Whilst pharmacological combinations remain clinically unsupported for retatrutide at this stage, there is robust evidence that certain lifestyle interventions can meaningfully complement weight-loss pharmacotherapy
adults have used a GLP-1 agonist medication and 79% of employers have seen an increased interest in GLP-1s among covered employees